IGC Pharma, Inc.IGCNYSE
Loading
Year-over-year revenue growth rate
3Y CAGR
+9.0%/yr
vs +75.1%/yr prior
Acceleration
-66.1pp
Decelerating
Percentile
P87
Within normal range
vs 3Y Ago
1.3x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 83.25% |
| Q3 2025 | -41.77% |
| Q2 2025 | -0.61% |
| Q1 2025 | 28.40% |
| Q4 2024 | -37.62% |
| Q3 2024 | 51.47% |
| Q2 2024 | -7.80% |
| Q1 2024 | 44.61% |
| Q4 2023 | -29.90% |
| Q3 2023 | -47.57% |
| Q2 2023 | 234.34% |
| Q1 2023 | -50.00% |
| Q4 2022 | 64.36% |
| Q3 2022 | -4.72% |
| Q2 2022 | 73.77% |
| Q1 2022 | -14.08% |
| Q4 2021 | 153.57% |
| Q3 2021 | -27.27% |
| Q2 2021 | -4.94% |
| Q1 2021 | -25.00% |
| Q4 2020 | -13.60% |
| Q3 2020 | -78.60% |
| Q2 2020 | 1913.79% |
| Q1 2020 | -94.94% |
| Q4 2019 | -68.53% |
| Q3 2019 | 10.43% |
| Q2 2019 | 6.94% |
| Q1 2019 | 20.00% |
| Q4 2018 | 58.45% |
| Q3 2018 | -45.11% |
| Q2 2018 | 29.38% |
| Q1 2018 | 49.87% |
| Q4 2017 | 223.37% |
| Q3 2017 | 345.24% |
| Q2 2017 | -43.32% |
| Q1 2017 | -62.65% |
| Q4 2016 | 54.17% |
| Q3 2016 | -43.79% |
| Q2 2016 | -78.91% |
| Q1 2016 | 26.08% |